Somatropin intranasal - Adhera Therapeutics
Latest Information Update: 02 Oct 2021
At a glance
- Originator Nastech Pharmaceutical Company
- Developer Marina Biotech
- Class Growth hormones; Hormonal replacements; Obesity therapies; Recombinant proteins
- Mechanism of Action Human growth hormone replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Somatotropin deficiency
Most Recent Events
- 03 Feb 2017 Discontinued - Phase-I for Somatotropin deficiency in USA (Intranasal)
- 09 Jun 2004 Suspended - Phase-I for Somatotropin deficiency in USA (Intranasal)
- 05 Nov 2001 Phase-I clinical trials for Somatotropin deficiency in USA (Intranasal)